Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1 domain family member 25 (TBC1D25)
- Target
- TBC1D25
- Molecular classification
- Other (Rab GTPase-activating protein), Enzyme (GTPase activator activity)
01
Overview
TBC1 domain family member 25 (TBC1D25) is a protein-coding gene encoding a member of the TBC (Tre-2/Bub2/Cdc16) domain-containing Rab GTPase-activating proteins. It is involved in the regulation of autophagosome maturation through its GTPase activator activity, specifically targeting RAB33B, and mediates the fusion of autophagosomes with endosomes and lysosomes[2][4][6][7]. TBC1D25 is also implicated in pathological cardiac remodeling, acting to suppress the TAK1-JNK/p38 signaling pathway, thereby providing a potential protective role against cardiac hypertrophy and heart failure[1]. The gene has been linked to diseases such as oligospermia and spindle cell synovial sarcoma, but its primary research focus is currently in cardiovascular pathology and basic autophagy physiology.
- Other names
- OATL1MG81Ornithine aminotransferase-like 1TBC25
02
Mechanism of action
Not established for direct therapeutic intervention; studies suggest modulation of the TAK1-JNK/p38 pathway for cardiac protection[1].
03
Biological functions
Regulation of autophagosome maturationGTPase activator activityRegulation of fusion of autophagosomes with endosomes and lysosomesNegative regulation of cardiac remodeling (via inhibition of TAK1-JNK/p38 signaling pathway)
04
Disease associations
Cardiovascular disease (cardiac remodeling, heart failure)[1]Oligospermia[2]Spindle cell synovial sarcoma[2]
05
Safety considerations
No specific safety concerns or therapeutic challenges documented; function in autophagy and cardiac remodeling suggests pleiotropic effects, but clinical safety not established.
06
Biomarkers
Increased TBC1D25 expression as a marker for cardiac remodeling progression in preclinical models[1]
Beyond the preview
Go deeper on TBC1 domain family member 25 (TBC1D25).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBC1 domain family member 25 (TBC1D25).